Siriraj Medical Journal (Nov 2023)
Clinical trial of glibenclamide (HB 419)
Abstract
A clinical trial of HB 419 in 44 ambulant adult diabetics considered suitable for oral therapy was carried out at the Thailand Tobacco Monopoly Hospital, Bangkok. The subjects comprised 38 patients (20 men and 18 women) with an average age of 50.9 years, who previously had received other oral antidiabetic drugs (sulfonylurea derivatives, biguanid), and 6 recently diagnosed patients who had never been treated before. The duration of treatment was between 3-6 months (average 4.5 months). Satisfactory metabolic control was achieved in 97.37 per cent and 100 per cent of the patients in the two groups respectively. 73.68 per cent of the previously treated patients were controlled with HB 419 in a daily maintenance dose of 5 mg. or less. There was primary failure in 2.63 per cent, but no incipient secondary failure. As a whole the drug was well tolerated. No significant side-effects occurred. Larger daily doses should be divided. None of the laboratory tests (bilirubin and alkaline phosphatase determinations, platelets counts and urinalysis) showed remarkable changes.
